Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases
スポンサーリンク
概要
- 論文の詳細を見る
We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.
論文 | ランダム
- インスリン族ペプチド、ボンビキシンの受容体の検索 : 動物
- タバコスズメガの前胸腺刺激ホルモンcDNAクローニング : 有機化学・天然物化学
- 5-42 液体ヘリウム急速凍結法による免疫電顕(5.植物の無機栄養および養分吸収)
- G304 カイコ性フェロモン生合成活性化神経ペプチドの産生・輸送器官について(生化学)
- 昆虫の脱皮・変態にかかわる脳神経ペプチド